Diabetes Research and Clinical Practice 2012-06-01

Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.

Kathleen M Dungan, John B Buse, William H Herman, Richard F Arakaki, Honghua H Jiang, Jennie G Jacobson, Jessie L Fahrbach

Index: Diabetes Res. Clin. Pract. 96(3) , e66-9, (2012)

Full Text: HTML

Abstract

Endpoint HbA(1c) <7.0% was achieved by 80 (73.4%) lispro mix 25 (LM25)-treated patients and 67 (60.9%) glargine-treated patients (p=0.027) with baseline 1,5 anhydroglucitol (1,5AG) below median and 75 (70.8%) LM25-treated patients and 72 (63.7%) glargine-treated patients (p=0.238) with 1,5AG≥median, suggesting, 1,5AG may offer therapeutic insight when starting insulin therapy.Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.